WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 317193
CAS#: 117-37-3
Description: Anisindione (brand name Miradon) is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K–mediated gamma-carboxylation of precursor proteins.
MedKoo Cat#: 317193
Name: Anisindione
CAS#: 117-37-3
Chemical Formula: C16H12O3
Exact Mass: 252.07864
Molecular Weight: 252.26
Elemental Analysis: C, 76.18; H, 4.79; O, 19.03
Synonym: Miradon; Anisin indandione; Unidone
IUPAC/Chemical Name: 2-(4-methoxyphenyl)indene-1,3-dione
InChi Key: XRCFXMGQEVUZFC-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
SMILES Code: COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 252.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Spyropoulos AC, Hayth KA, Jenkins P. Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. PubMed PMID: 12680483.
2: Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol. 2000 Jun;95(6 Pt 1):938-40. PubMed PMID: 10831996.
3: Grosset AB, Allen JE, Rodgers GM. Anticoagulation with anisindione in patients who are intolerant of warfarin. Am J Hematol. 1994 Jun;46(2):138-40. PubMed PMID: 8172181.
4: Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994 May;10(5):381-94. Review. PubMed PMID: 8037888.
5: Murthy AR, Wyrick SD, Hall IH. Hypolipidemic activity of indan-1,3-dione derivatives in rodents. J Med Chem. 1985 Nov;28(11):1591-6. PubMed PMID: 4067989.
6: GIBELLI A, DELUTTEROTTI A. [RESEARCH ON THE ANTICOAGULANT ACTION OF AN INDANDIONE DERIVATIVE (ANISINDIONE) WITH PROLONGED ACTION]. Rass Int Clin Ter. 1964 Jan 15;44:1-8. Italian. PubMed PMID: 14126507.
7: WILLIS PW 3rd, ZWEIFLER AJ. An evaluation of anisindione, a new and useful oral anticoagulant. Preliminary report. J Mich State Med Soc. 1962 Nov;61:1386-7. PubMed PMID: 14000965.
8: BUZZI A, CARBAJAL B. [Clinical evaluation of the anticoagulant, anisindione]. Prensa Med Argent. 1961 Jun 23;48:1826-9. Spanish. PubMed PMID: 13875273.
9: FIELDER FG, HOFF EJ, BOLLES S, SIEGRIST JC. A study of the chronic toxicity of anisindione and phenylindanedione in dogs. Toxicol Appl Pharmacol. 1961 Jan;3:122-6. PubMed PMID: 13699368.
10: CONNELL WF, MAYER GA. Evaluation of anticoagulant therapy with anisindione (miradon). Can Med Assoc J. 1959 May 15;80(10):785-90. PubMed PMID: 13652026; PubMed Central PMCID: PMC1831018.
